Filtered By:
Specialty: Hematology
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 643 results found since Jan 2013.

Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011 –2016
We used Danish nationwide registries to examine temporal trends in the predicted stroke and bleeding risks (mean CHA2DS2-VASc and HAS-BLED scores per year, respectively) as well as the combination of selected stroke and bleeding risk factors per year among atrial fibrillation (AF) patients initiated for the first time between 2011 and 2016 on vitamin K antagonists (VKAs), dabigatran, rivaroxaban, or apixaban.
Source: Thrombosis Research - October 16, 2017 Category: Hematology Authors: Alexandar Dukanovic, Laila Staerk, Emil Loldrup Fosb øl, Kasper Gadsbøll, Gunnar Hilmar Gislason, Jonas Bjerring Olesen Tags: Full Length Article Source Type: research

Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation
In conclusion, we determined the trough and peak levels of AFXaA in patients with NVAF while being treated with the apixa ban in Korea. Our results could be used as a starting point when setting the reference ranges for laboratories using anti-Xa assay. Large-scale studies are needed to establish the reference range for AFXaA in patients with NVAF.
Source: Journal of Thrombosis and Thrombolysis - December 2, 2017 Category: Hematology Source Type: research

Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence
Patients who receive antithrombotic therapy as secondary prevention in the early phase of non valvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) have a better prognosis compared with patients who do not receive antithrombotic treatment [1]. In the VISTA registry the incidence of stroke recurrence, symptomatic intracranial bleeding, all-cause mortality and 90-day modified Rankin Scale (mRS) ≥4 in patients with NVAF-related AIS not receiving antithrombotic treatment was 19.8%, 9.3%, 40.7% and 65.3%, respectively compared with patients receiving vitamin K antagonists (VKAs) (10.6%, 2.9%, 25.5% and 46.6%...
Source: Thrombosis Research - November 3, 2018 Category: Hematology Authors: Luca Masotti, Elisa Grifoni, Alessandro Dei, Vieri Vannucchi, Federico Moroni, Stefano Spolveri, Grazia Panigada, Giancarlo Landini Tags: Letter to the Editors-in-Chief Source Type: research

Stroke in a Pediatric Immune Thrombocytopenia Case
Conclusion: Stroke in the immune thrombocytopenic clinic is a rare but hard to manage condition. Although its mechanism not understand well, the clinician should be identify and manage it carefully.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Leblebisatan, G., Cil, M., Sasmaz, H. I., Kilinc, Y., Soyupak, S. Tags: 311. Disorders of Platelet Number or Function Source Type: research

Direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: focus on real life studies
AbstractStrong evidence for the use of direct oral anticoagulants (DOACs) in the early phase of non valvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) is lacking, because this kind of patients were excluded from phase III randomized clinical trials (RCT) and ad hoc RCTs are ongoing. In the latest years a lot of real life studies on this topic have been published. The aim of our review was to focus on these. We reviewed the PubMed databases searching articles reporting on DOACs starting time within 2 weeks from AIS onset. We selected fifteen studies, eight with retrospective, six with prospective observ...
Source: Journal of Thrombosis and Thrombolysis - November 23, 2018 Category: Hematology Source Type: research

Survey of confidence in use of stroke and bleeding risk calculators, knowledge of anticoagulants, and comfort with prescription of anticoagulation in challenging scenarios: SUPPORT-AF II study
AbstractHalf of patients with atrial fibrillation (AF) and elevated stroke risk do not receive anticoagulation (AC). Explanations for undertreatment may relate to provider lack of confidence with or knowledge of the CHA2DS2-VASc stroke calculator, unfamiliarity with direct oral anticoagulants (DOACs), or uncertainty about use of AC after bleeding events or other challenging patient scenarios. We surveyed cardiology and primary care providers (PCPs) within a large healthcare system to investigate prescriber knowledge, confidence, and comfort prescribing AC for AF in challenging scenarios. Of 112 providers invited, 70 (63%) ...
Source: Journal of Thrombosis and Thrombolysis - September 10, 2019 Category: Hematology Source Type: research

Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review.
CONCLUSION:  The higher risk profiles of patients in OSs versus RCTs, and higher rates of both bleeding and mortality not attributable to thromboembolism in patients treated with apixaban 2.5 versus 5 mg twice daily suggest that differences in patient characteristics are additional important contributors to the higher than expected thromboembolic event rates in clinical practice. PMID: 32668484 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 14, 2020 Category: Hematology Authors: de Vries TAC, Hirsh J, Xu K, Mallick I, Bhagirath VC, Eikelboom JW, Ginsberg JS, Kruger PC, Chan NC Tags: Thromb Haemost Source Type: research

Thrombectomy for ischemic stroke with large vessel occlusion and concomitant subarachnoid hemorrhage
AbstractTo report our experience in treating one patient with nontraumatic subarachnoid hemorrhage (SAH) and concurrent acute ischemic stroke (AIS) due to large vessels occlusion (LVO). A man in his 50  s presented with acute right hemiparesis and aphasia. Brain CT showed a SAH in the left central sulcus; CT-angiography revealed a tandem occlusion of the left internal carotid artery and homolateral middle cerebral artery. He underwent an angiographic procedure with successful recanalization. Foll ow-up CT demonstrated a striatal-lenticular stroke without SAH progression. While the absolute contraindication to IVT during i...
Source: Journal of Thrombosis and Thrombolysis - June 8, 2021 Category: Hematology Source Type: research

Oral Anticoagulation Timing in Patients with Acute Ischaemic Stroke and Atrial Fibrillation
CONCLUSIONS: In AF patients with severe AIS, early OAC use before the guideline-recommended days appeared to increase the risk of bleeding events, although the OAC initiation time seemed not to affect the risk of serious vascular events. The optimal severity-specific timing for OAC initiation after AIS requires further evaluation.PMID:34649296 | DOI:10.1055/a-1669-4987
Source: Thrombosis and Haemostasis - October 14, 2021 Category: Hematology Authors: Po-Yin Chang Weiting Wang Wei-Lun Wu Hui-Chin Chang Chen-Huan Chen Yi-Wen Tsai Shih-Hwa Chiou Gregory Yh Lip Hao-Min Cheng Chern-En Chiang Source Type: research

Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke
In conclusion, administration of a bispecific inhibitor against TAFI and PAI-1 results in a prominent profibrinolytic effect in mice without increased bleeding.
Source: Blood - February 19, 2015 Category: Hematology Authors: Wyseure, T., Rubio, M., Denorme, F., Martinez de Lizarrondo, S., Peeters, M., Gils, A., De Meyer, S. F., Vivien, D., Declerck, P. J. Tags: Thrombosis and Hemostasis Source Type: research

A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL‐2)
ConclusionsIn this Phase II study in patients with NVAF, a lower bleeding rate was observed in the 120 mg daily darexaban group compared with warfarin with a reduction in plasma D‐dimer as marker for hemostasis. Further investigation of the optimal dose of darexaban for the prevention of stroke in patients with NVAF would need to be considered.
Source: Journal of Thrombosis and Haemostasis - July 15, 2015 Category: Hematology Authors: G. Y. H. Lip, J. L. Halperin, P. Petersen, G. M. Rodgers, D. Pall, R. W. Renfurm Tags: Original Article Source Type: research

Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice
Von Willebrand factor (VWF) is a key hemostatic protein synthesized in both endothelial cells and megakaryocytes. Megakaryocyte-derived VWF is stored in α-granules of platelets and is enriched in hyperactive "ultra-large" VWF multimers. To elucidate the specific contribution of platelet VWF in hemostasis and thrombosis, we performed crossed bone marrow transplantations between C57BL/6J and Vwf–/– mice to generate chimeric mice. Chimeric mice specifically lacking platelet VWF showed normal tail bleeding and carotid artery thrombosis, similar to wild-type mice. Chimeric mice with VWF present only in platele...
Source: Blood - October 1, 2015 Category: Hematology Authors: Verhenne, S., Denorme, F., Libbrecht, S., Vandenbulcke, A., Pareyn, I., Deckmyn, H., Lambrecht, A., Nieswandt, B., Kleinschnitz, C., Vanhoorelbeke, K., De Meyer, S. F. Tags: Platelets and Thrombopoiesis, Thrombosis and Hemostasis Source Type: research

Thrombelastography does not predict clinical response to rtPA for acute ischemic stroke
Abstract Thrombelastography (TEG) measures coagulation in venous blood. We hypothesized that TEG, by reflecting clot subtype and ex vivo fibrinolysis, might predict fibrinolytic response to tPA as reflected by rapid clinical improvement or hemorrhagic transformation of the infarct. 171 acute ischemic stroke patients treated with tPA were prospectively enrolled. Venous blood for TEG was drawn before and 10 min after tPA bolus. We measured rapid clinical improvement (RCI = 8 point improvement on NIHSS or total NIHSS of 0, 1 at 36 h), Hemorrhagic transformation (HT = any blood on imaging within 36 h), and hyp...
Source: Journal of Thrombosis and Thrombolysis - March 23, 2016 Category: Hematology Source Type: research

The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non‐valvular atrial fibrillation: comment
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 30, 2016 Category: Hematology Authors: Simon Mantha, Stephan Moll, Patrick Hilden, Sean Devlin, Adam Rose Tags: Letter ‐ to the Editor Source Type: research

Optimizing Stroke and Bleeding Risk Assessment in Patients with Atrial Fibrillation: A Balance of Evidence, Practicality and Precision.
Abstract PMID: 30458556 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 20, 2018 Category: Hematology Authors: Proietti M, Mujovic N, Potpara TS Tags: Thromb Haemost Source Type: research